{"title":"mRNA 技术在登革热病毒疫苗开发中的机遇与挑战","authors":"Xiaoyang Liu, Daniel Salmon","doi":"arxiv-2409.10805","DOIUrl":null,"url":null,"abstract":"Dengue virus (DENV) is a mosquito-borne virus with a significant human health\nconcern. With 390 million infections annually and 96 million showing clinical\nsymptoms, severe dengue can lead to life-threatening conditions like dengue\nhemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved\nvaccine, Dengvaxia, has limitations due to antibody-dependent enhancement\n(ADE), necessitating careful administration. The recent pre-approval of TAK-003\nby WHO in 2024 highlights ongoing efforts to improve vaccine options. This\nreview explores recent advancements in dengue vaccine development, emphasizing\npotential utility of mRNA-based vaccines. By examining current clinical trial\ndata and innovations, we aim to identify promising strategies to address the\nlimitations of existing vaccines and enhance global dengue prevention efforts.","PeriodicalId":501219,"journal":{"name":"arXiv - QuanBio - Other Quantitative Biology","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine\",\"authors\":\"Xiaoyang Liu, Daniel Salmon\",\"doi\":\"arxiv-2409.10805\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dengue virus (DENV) is a mosquito-borne virus with a significant human health\\nconcern. With 390 million infections annually and 96 million showing clinical\\nsymptoms, severe dengue can lead to life-threatening conditions like dengue\\nhemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved\\nvaccine, Dengvaxia, has limitations due to antibody-dependent enhancement\\n(ADE), necessitating careful administration. The recent pre-approval of TAK-003\\nby WHO in 2024 highlights ongoing efforts to improve vaccine options. This\\nreview explores recent advancements in dengue vaccine development, emphasizing\\npotential utility of mRNA-based vaccines. By examining current clinical trial\\ndata and innovations, we aim to identify promising strategies to address the\\nlimitations of existing vaccines and enhance global dengue prevention efforts.\",\"PeriodicalId\":501219,\"journal\":{\"name\":\"arXiv - QuanBio - Other Quantitative Biology\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"arXiv - QuanBio - Other Quantitative Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/arxiv-2409.10805\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Other Quantitative Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2409.10805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine
Dengue virus (DENV) is a mosquito-borne virus with a significant human health
concern. With 390 million infections annually and 96 million showing clinical
symptoms, severe dengue can lead to life-threatening conditions like dengue
hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved
vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement
(ADE), necessitating careful administration. The recent pre-approval of TAK-003
by WHO in 2024 highlights ongoing efforts to improve vaccine options. This
review explores recent advancements in dengue vaccine development, emphasizing
potential utility of mRNA-based vaccines. By examining current clinical trial
data and innovations, we aim to identify promising strategies to address the
limitations of existing vaccines and enhance global dengue prevention efforts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
